$VRNA
Verona Pharma PLC Stock $vrna

$vrna Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000165731222000038 Filed on November 09, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$458.0K	$0.00	$40.00M
YoY Change		-100.0%
Cost Of Revenue	$346.0K
YoY Change
Gross Profit	$112.0K	$0.00	$40.00M
YoY Change		-100.0%
Gross Profit Margin	24.45%		100.0%
Selling, General & Admin	$8.323M	$5.290M	$10.88M
YoY Change	44.57%	-51.39%	-0.34%
% of Gross Profit	7431.25%		27.21%
Research & Development	$6.838M	$9.838M	$22.56M
YoY Change	-69.89%	-56.39%	75.98%
% of Gross Profit	6105.36%		56.4%
Depreciation & Amortization	$151.0K	$157.0K	$162.0K
YoY Change	-6.79%	-3.09%	-53.71%
% of Gross Profit	134.82%		0.41%
Operating Expenses	$15.16M	$15.13M	$33.44M
YoY Change	-46.74%	-54.76%	58.47%
Operating Profit	-$15.05M	-$15.13M	$6.557M
YoY Change		-330.72%	-131.07%
Interest Expense	$4.645M	$116.0K	$86.00K
YoY Change	-22219.05%	34.88%
% of Operating Profit			1.31%
Other Income/Expense, Net	$796.0K	-$455.0K	$4.621M
YoY Change	-84.0%	-109.85%	108.43%
Pretax Income	-$10.42M	-$15.58M	$11.18M
YoY Change	-55.67%	-239.41%	-159.18%
Income Tax	$28.00K	$64.00K	$127.0K
% Of Pretax Income			1.14%
Net Earnings	-$10.45M	-$15.65M	$11.05M
YoY Change	-55.07%	-241.59%	-158.38%
Net Earnings / Revenue	-2281.88%		27.63%
Basic Earnings Per Share		-$0.03	$0.02
Diluted Earnings Per Share	-$0.02	-$0.03	$0.02
COMMON SHARES
Basic Shares Outstanding	605.0M shares	487.6M shares	475.3M shares
Diluted Shares Outstanding		544.1M shares	515.8M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$227.8M	$231.7M	$166.5M
YoY Change	53.54%	39.12%	-36.16%
Cash & Equivalents	$227.8M	$231.7M	$166.5M
Short-Term Investments
Other Short-Term Assets	$3.388M	$3.077M	$667.0K
YoY Change	64.23%	361.32%	-88.88%
Inventory
Prepaid Expenses	$2.499M	$3.355M	$6.672M
Receivables
Other Receivables
Total Short-Term Assets	$243.0M	$258.5M	$184.5M
YoY Change	42.89%	40.09%	-32.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$73.00K	$81.00K	$88.00K
YoY Change	-8.75%	-7.95%	-94.82%
Goodwill	$545.0K	$544.0K	$545.0K
YoY Change	0.0%	-0.18%
Intangibles
YoY Change
Long-Term Investments	$15.00M	$15.00M	$15.00M
YoY Change	0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$16.47M	$16.42M	$17.07M
YoY Change	-0.31%	-3.81%	-60.4%
TOTAL ASSETS
Total Short-Term Assets	$243.0M	$258.5M	$184.5M
Total Long-Term Assets	$16.47M	$16.42M	$17.07M
Total Assets	$259.5M	$274.9M	$201.6M
YoY Change	39.06%	36.37%	-36.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.910M	$8.002M	$9.000K
YoY Change	-71.03%	88811.11%	-99.95%
Accrued Expenses	$13.75M	$22.98M	$26.46M
YoY Change	-38.21%	-13.15%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$19.03M	$32.13M	$27.74M
YoY Change	-43.06%	15.82%	27.25%
LONG-TERM LIABILITIES
Long-Term Debt	$9.768M	$5.000M	$4.800M
YoY Change	100.41%	4.17%	433.33%
Other Long-Term Liabilities	$205.0K	$224.0K	$797.0K
YoY Change	-28.32%	-71.89%	-97.98%
Total Long-Term Liabilities	$9.973M	$5.259M	$5.618M
YoY Change	93.28%	-6.39%	-86.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.03M	$32.13M	$27.74M
Total Long-Term Liabilities	$9.973M	$5.259M	$5.618M
Total Liabilities	$29.00M	$37.39M	$33.36M
YoY Change	-24.83%	12.08%	-46.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$333.1M	-$322.4M	-$240.3M
YoY Change	26.31%	34.17%
Common Stock	$40.53M	$39.12M	$31.86M
YoY Change	27.22%	22.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.549M	$449.0K	$770.0K
YoY Change	156.88%	-41.69%
Treasury Stock Shares
Shareholders Equity	$230.5M	$237.5M	$168.2M
YoY Change
Total Liabilities & Shareholders Equity	$259.5M	$274.9M	$201.6M
YoY Change	39.06%	36.37%	-36.52%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$10.45M	-$15.65M	$11.05M
YoY Change	-55.07%	-241.59%	-158.38%
Depreciation, Depletion And Amortization	$151.0K	$157.0K	$162.0K
YoY Change	-6.79%	-3.09%	-53.71%
Cash From Operating Activities	-$7.738M	-$18.10M	$22.83M
YoY Change	-55.33%	-179.28%	-237.25%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$11.00K
YoY Change	-100.0%	-100.0%	-95.42%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change			-100.0%
Cash From Investing Activities	$0.00	$0.00	-$11.00K
YoY Change	-100.0%	-100.0%	-100.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.614M	139.6M	-1.817M
YoY Change	-390.12%	-7784.04%	-100.76%
NET CHANGE
Cash From Operating Activities	-7.738M	-18.10M	22.83M
Cash From Investing Activities	0.000	0.000	-11.00K
Cash From Financing Activities	2.614M	139.6M	-1.817M
Net Change In Cash	-5.124M	121.5M	21.00M
YoY Change	-71.88%	478.77%	-90.65%
FREE CASH FLOW
Cash From Operating Activities	-$7.738M	-$18.10M	$22.83M
Capital Expenditures	$0.00	$0.00	-$11.00K
Free Cash Flow	-$7.738M	-$18.10M	$22.84M
YoY Change	-55.33%	-179.24%	-239.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001657312
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38067
	dei	Entity Registrant Name EntityRegistrantName	Verona Pharma plc
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1489389
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3 More London Riverside
	dei	Entity Address City Or Town EntityAddressCityOrTown	London
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	SE1 2RE
	dei	Entity Address Country EntityAddressCountry	GB
	dei	Country Region CountryRegion	44
	dei	City Area Code CityAreaCode	203
	dei	Local Phone Number LocalPhoneNumber	283 4200
	dei	Security12b Title Security12bTitle	Ordinary shares, nominal value £0.05 per share*
	dei	Trading Symbol TradingSymbol	VRNA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	604980598	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	231701000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148380000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3355000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4037000	usd
CY2022Q3	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	20321000	usd
CY2021Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	15583000	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	3077000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2063000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	258454000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	170063000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	81000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	544000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	545000	usd
CY2022Q3	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	793000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	899000	usd
CY2022Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	16418000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	16524000	usd
CY2022Q3	us-gaap	Assets Assets	274872000	usd
CY2021Q4	us-gaap	Assets Assets	186587000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	8002000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10044000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22978000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22256000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	569000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	648000	usd
CY2022Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	285000	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	147000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	294000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	327000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	32128000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	33422000	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5035000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4874000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	224000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	286000	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5259000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5160000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	37387000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	38582000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	608138246	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	489177550	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	602215606	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	480082966	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	39119000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	31855000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	525858000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	385070000	usd
CY2022Q3	us-gaap	Treasury Stock Value TreasuryStockValue	449000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	603000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-322442000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-263716000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	237485000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	148005000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	274872000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	186587000	usd
CY2022Q3	us-gaap	Revenues Revenues	0	usd
CY2021Q3	us-gaap	Revenues Revenues	40000000	usd
	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	40000000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	0	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	40000000	usd
	us-gaap	Gross Profit GrossProfit	0	usd
	us-gaap	Gross Profit GrossProfit	40000000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9838000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22560000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42445000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56697000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5290000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10883000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18256000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28150000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	15128000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	33443000	usd
	us-gaap	Operating Expenses OperatingExpenses	60701000	usd
	us-gaap	Operating Expenses OperatingExpenses	84847000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-15128000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	6557000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-60701000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-44847000	usd
CY2022Q3	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	2127000	usd
CY2021Q3	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	4749000	usd
	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	8838000	usd
	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	10655000	usd
CY2022Q3	us-gaap	Investment Income Net InvestmentIncomeNet	779000	usd
CY2021Q3	us-gaap	Investment Income Net InvestmentIncomeNet	4000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	959000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	11000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	116000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	86000	usd
	us-gaap	Interest Expense InterestExpense	291000	usd
	us-gaap	Interest Expense InterestExpense	255000	usd
CY2022Q3	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	0	usd
CY2021Q3	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	40000	usd
	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	0	usd
	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	2244000	usd
CY2022Q3	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	-3245000	usd
CY2021Q3	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	-86000	usd
	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	-6830000	usd
	vrna	Foreign Currency Transaction Gain Loss Before Tax Excluding Finance Leases ForeignCurrencyTransactionGainLossBeforeTaxExcludingFinanceLeases	117000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-455000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4621000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2676000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12772000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15583000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11178000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-58025000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32075000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	64000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	127000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	225000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	232000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-15647000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	11051000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-58250000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-32307000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	544134136	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	475334354	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	503751844	shares
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	110880000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-15647000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	471159171	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	544134136	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	515819439	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	503751844	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	471159171	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	148005000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24837000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	67000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	793000	usd
CY2022Q1	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	-118000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3747000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	126307000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-17766000	usd
CY2022Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	689000	usd
CY2022Q2	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	25000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3053000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	140148000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	371000	usd
CY2022Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	900000	usd
CY2022Q3	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	182000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2815000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	237485000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	184854000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-21290000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8850000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	172414000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-22068000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	383000	usd
CY2021Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3782000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7450000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	154397000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	11051000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	350000	usd
CY2021Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2167000	usd
CY2021Q3	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	367000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4938000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	168202000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-58250000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-32307000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7105000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-556000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	67000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	92000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	94000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	94000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2244000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9617000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	21238000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	485000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	467000	usd
	vrna	Increase Decrease In Equity Interest Receivable IncreaseDecreaseInEquityInterestReceivable	0	usd
	vrna	Increase Decrease In Equity Interest Receivable IncreaseDecreaseInEquityInterestReceivable	15000000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-682000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2134000	usd
	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	9113000	usd
	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	2677000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1014000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1053000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	351000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	823000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2042000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-169000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	722000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	15595000	usd
	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-141000	usd
	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	177000	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	138000	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	451000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-123000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-300000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52124000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15931000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9582000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2382000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5949000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	371000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	138204000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5216000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2730000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-281000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	83321000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21439000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148380000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187986000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231701000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	166547000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	90000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	190000	usd
	us-gaap	Interest Paid Net InterestPaidNet	162000	usd
	vrna	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1	subsidiary
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-322400000	usd
CY2022Q3	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022Q3	vrna	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	20321000	usd
CY2021Q4	vrna	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	15583000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses, the fair value of share-based compensation, the fair value of warrants, research and development tax credit and the carrying value of the equity interest in Nuance Pharma (as defined below). Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company’s estimates.</span></div>
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.38
CY2022Q3	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	20321000	usd
CY2021Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	15583000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	608000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.62
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13303200	shares
CY2022Q3	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	19677000	usd
CY2021Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	21336000	usd
CY2022Q3	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	1746000	usd
CY2021Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	919000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1555000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22978000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22256000	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5000000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.34
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1760000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	301168	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.77
CY2022Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	502232	shares
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2816000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4938000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9617000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21238000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12695200	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.51
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15063200	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.24
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4520000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.82
CY2022Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.74
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18779800	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.16
CY2022Q3	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-15647000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	11051000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-58250000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-32307000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	544134136	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	475334354	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	503751844	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	471159171	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	544134136	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	515819439	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	503751844	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	471159171	shares
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	57650632	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25139377	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	57650632	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	65624462	shares
CY2022Q3	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	1500000	usd

Files In Submission

Name	View Source	Status
0001657312-22-000038-index-headers.html	Edgar Link	pending
0001657312-22-000038-index.html	Edgar Link	pending
0001657312-22-000038.txt	Edgar Link	pending
0001657312-22-000038-xbrl.zip	Edgar Link	pending
exhibit311q322.htm	Edgar Link	pending
exhibit312q322.htm	Edgar Link	pending
exhibit321q322.htm	Edgar Link	pending
exhibit322q322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vrna-20220930.htm	Edgar Link	pending
vrna-20220930.xsd	Edgar Link	pending
vrna-20220930_cal.xml	Edgar Link	unprocessable
vrna-20220930_def.xml	Edgar Link	unprocessable
vrna-20220930_lab.xml	Edgar Link	unprocessable
vrna-20220930_pre.xml	Edgar Link	unprocessable
vrna-20220930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRNA
Verona Pharma PLC Stock $vrna

2022 Q4 Form 10-Q Financial Statement

#000165731222000038 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA Verona Pharma PLC Stock $vrna

2022 Q4 Form 10-Q Financial Statement

#000165731222000038 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA
Verona Pharma PLC Stock $vrna